1. Home
  2. DH vs INDP Comparison

DH vs INDP Comparison

Compare DH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$0.95

Market Cap

112.1M

Sector

Technology

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.85

Market Cap

125.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
INDP
Founded
2011
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.1M
125.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DH
INDP
Price
$0.95
$3.85
Analyst Decision
Hold
Analyst Count
5
0
Target Price
★ $3.08
N/A
AVG Volume (30 Days)
1.1M
★ 1.4M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.28
N/A
EPS
N/A
★ N/A
Revenue
★ $241,521,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.74
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.61
$0.92
52 Week High
$4.06
$5.96

Technical Indicators

Market Signals
Indicator
DH
INDP
Relative Strength Index (RSI) 53.80 64.42
Support Level $0.91 $1.73
Resistance Level $1.01 $3.84
Average True Range (ATR) 0.05 0.62
MACD -0.01 0.13
Stochastic Oscillator 40.09 85.08

Price Performance

Historical Comparison
DH
INDP

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: